Why the study?
Anthracyclines can cause significant cardiotoxicity that restricts clinical use, making early monitoring and mitigation strategies an urgent clinical problem.
This review summarizes current knowledge on the mechanisms, early monitoring, and prevention of anthracycline-induced cardiotoxicity to guide clinical management in cardio-oncology.
Answers are grounded in this paper and cite their sources.
Informs cardio-oncology monitoring and prevention; leaves open prospective validation of emerging strategies.
Anthracyclines represent a highly efficacious class of chemotherapeutic agents employed extensively in antitumor therapy. They are universally recognized for their potency in treating diverse malignancies, encompassing breast cancer, gastrointestinal tumors, and lymphomas. Nevertheless, the accumulation of anthracyclines within the body can lead to significant cardiac toxicity, adversely impacting both the survival rates and quality of life for tumor patients. This limitation somewhat restricts their clinical utilization. Determining how to monitor and mitigate their cardiotoxicity at an early stage has become an urgent clinical problem to be solved. Therefore, this paper reviews the mechanism of action, early monitoring, and strategies for the prevention of anthracycline-induced cardiotoxicity for clinical reference.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: